News
LX4211 combination therapy found to treat type 2 diabetes
Lexicon Pharmaceuticals has announced the top-line results from the first clinical study evaluating the combined effects of LX4211, a sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin. ...
News
Apricus, Abbott strike deal to commercialize Vitaros in Canada
Apricus Biosciences has signed a licensing deal with Abbott Laboratories, as per which Abbott will receive the exclusive rights to market Apricus Bio's Vitaros  in Canada. Vitaros (alprostadil), indicated to treat erectile dysfunction (ED) is...
News
Novartis AG recalls 4 over-the-counter drugs
Novartis AG said Sunday it is voluntarily recalling some over-the-counter products in the U.S., including its Excedrin headache pills and NoDoz medication, because they may contain broken or stray tablets from other products. The...
News
US FDA grants orphan drug status to CanBas’ CBP501 for malignant mesothelioma
CanBas Co, a clinical-stage biopharmaceutical company, has received orphan drug designation fro the United States Food and Drug Administration (FDA) for it's CBP501 "for use in combination with cisplatin and pemetrexed for treatment of patients with mesothelioma. ...
News
Acella Pharma acquires Prenate family of trademarks and associated IP
 Acella Pharmaceuticals, LLC,  a company that develops, markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products, acquires a leading US prenatal brand, Prenate family of trademarks and other associated intellectual property. ...
News
Lilly Recognized as One of the Best Places to Work for LGBT Equality
For the sixth consecutive year, Eli Lilly and Company has received a 100 percent rating on the Human Rights Campaign (HRC) Corporate Equality Index (CEI) for lesbian, gay, bisexual and transgender (LGBT) equality in the workplace. ...
News
BYETTA Approved for Use with Insulin Glargine in the U.S.
Amylin Pharmaceuticals, Inc., and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a new use for BYETTA® (exenatide) injection. BYETTA is now approved as an add-on therapy to insulin glargine, with...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read